Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VD2-2022: Daily oral vitamin D2 vs D3 dosing in adults with vitamin D deficiency
ChiCTR2400079573Phase 4Not yet recruiting
- Sponsor
- The Second Xiangya Hospital
- Start
- Jan 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of ergocalciferol and vitamin d in Vitamin D deficiency (VDD) (6 arms), sponsored by The Second Xiangya Hospital. Primary endpoints: Serum 25-hydroxyvitamin D3 at month 6, Serum 25-hydroxyvitamin D2 at month 6 and 1 more. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
ergocalciferolvitamin d
03
Conditions
Vitamin D deficiency (VDD)
Beyond the preview
Go deeper on ChiCTR2400079573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400079573.